Project description
Novel diagnostics and monitoring approach for immune-mediated diseases
Immune-mediated inflammatory diseases (IMID) include conditions with different aetiologies, characterised by common inflammatory pathways leading to inflammation and triggered by a dysregulation of the normal immune response. IMIDs are heterogeneous with regard to disease outcome and response to targeted therapies; predictive biomarkers are important for a precision medicine approach. Through the EU-funded ImmUniverse project, a transdisciplinary international consortium studies the role of crosstalk between tissue micro-environment and immune cells in disease progression and response to therapy of two IMIDs: ulcerative colitis and atopic dermatitis. The project will bring IMID diagnostics and treatment response monitoring to a new level by implementing non-invasive liquid-biopsy methodology combined with circulating biomarker assays.
Objective
Immune-mediated diseases (IMIDs) are an increasing medical burden in industrialized countries worldwide. IMIDs are characterized by an enormous heterogeneity with regard to disease outcome and response to targeted therapies, which currently cannot be adequately anticipated to tailor individual patient management. Hence, mechanistic understanding of this heterogeneity and biomarkers predictive for disease control and therapy response over time are important prerequisites of a future precision medicine in IMIDs. ImmUniverse has been formed as a European transdisciplinary consortium to tackle these unmet needs and to understand the role of the crosstalk between tissue microenvironment and immune cells in disease progression and response to therapy of two different IMIDs: ulcerative colitis and atopic dermatitis. Following this unique cross-disease approach ImmUniverse will fill the gap and the limitations of current studies, which do not systematically compare the complex interactions between recirculating immune cells and the respective tissue microenvironment. The consortium will combine analysis of tissue-derived signatures with “circulating signatures” detectable in liquid biopsies, employing state-of-the-art profiling technologies corresponding to multi-Omics datasets. The project will also bring diagnostics in IMID to a new level by implementing disruptive non-invasive liquid-biopsy methodology in combination with novel, validated circulating biomarker assays which are expected to improve diagnosis, inform early in the clinical course on disease severity and progression and enable treatment response monitoring. The identified signature will be validated to monitor state/progression and response to therapy in prospective observational cohorts. Realization of these objectives will result in improvement of patient management, lead to increased patient well-being and will significantly reduce the socioeconomic burden of these diseases.
Fields of science
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
20090 Pieve Emanuele
Italy
See on map
Participants (30)
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
20100 Rozzano (Mi)
See on map
1210 Wien
See on map
00161 Roma
See on map
24118 Kiel
See on map
CB2 1TN Cambridge
See on map
1081 HV Amsterdam
See on map
9052 ZWIJNAARDE - GENT
See on map
3000 Leuven
See on map
80539 MUNCHEN
See on map
8000 Aarhus C
See on map
8200 Aarhus
See on map
4365 ESCH-SUR-ALZETTE
See on map
8010 Graz
See on map
Participation ended
6525 XZ Nijmegen
See on map
54035 Nancy Cedex
See on map
4354 ESCH SUR ALZETTE
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
BRUSSELS Brussels / Bruxelles
See on map
1000 BRUXELLES
See on map
1000 Bruxelles / Brussel
See on map
66386 St Ingbert
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
56127 Pisa
See on map
TW89GS Brentford
See on map
65929 Frankfurt Am Main
See on map
RG21 4FA Basingstoke
See on map
4056 Basel
See on map
CT13 9NJ Sandwich
See on map
6525 GA Nijmegen
See on map
20132 Milano
See on map
89081 Ulm
See on map
3015 GD Rotterdam
See on map